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Abstract
Progression towards type 1 diabetes (T1D) in susceptible patients is linked to a progressive decline in the capacity of
regulatory T cells (Treg) to maintain tolerance. As such, therapies aimed at redressing the failing Treg compartment have
been the subject of intense investigation. Treg dysfunction in T1D has recently been linked to a reduced capacity of antigen
presenting cells (APCs) to maintain Treg function rather than Treg intrinsic defects. This suggests that therapies aimed
simply at addressing the failing Treg compartment are unlikely to provide long-term protection. Here, we demonstrate that
modulation of the inflammatory status of CD11b+CD11c2 APCs favors the upregulation of protective Tregs in a mouse
model of T1D. We further demonstrate that reduced expression of the costimulatory molecule CD40 plays a role in this
increased immunoregulatory capacity. Strikingly, Treg upregulation resulted exclusively from an increase in natural Tregs
rather than the peripheral conversion of conventional T cells. This suggests that modulation of CD11b+ CD11c2 APCs
inflammatory properties favors the establishment of natural Treg responses that, unlike adaptive Treg responses, are likely
to maintain tolerance to a broad range of antigens. As such, modulation of this APC subset represents a potential
therapeutic avenue to reestablish peripheral tolerance and protect from autoimmune diseases such as T1D.
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Introduction
Type 1 diabetes (T1D) is a T-cell mediated autoimmune disease
that results from the destruction of the insulin producing b cells of
the pancreas. In both humans and non-obese diabetic (NOD)
mice, a mouse model of T1D, disease development is progressive
and partial peripheral tolerance to islet antigens is only transiently
maintained [1]. Several reports have demonstrated an important
role for regulatory T cells (Tregs) in the maintenance of peripheral
tolerance towards pancreatic self-antigens [2–7]. Furthermore, in
both mice and humans a progressive loss of Treg suppressive
capacities correlates with disease development [8–11]. Recent data
suggest that the loss of suppressive capacity is not due to Treg
intrinsic defects but rather to a decreased capacity of antigen
presenting cells (APCs) to maintain Treg function [12,13]. In
NOD mice, CD11b+CD11c2 APCs are in part responsible for
the decrease in Treg suppressive function and this defect maps to
the well-described autoimmune diabetes susceptibility loci Idd3
[12]. Importantly, APCs from T1D patients are similarly defective
in their capacity to maintain Treg function [14]. Furthermore,
these same APCs present with an inflammatory phenotype that
could favor the development of potentially pathogenic IL-17-
producing T cells (Th17) [15]. Taken together, this suggests that
therapies aimed at modifying the APC response may allow for the
reestablishment of peripheral tolerance and allow for long-term
protection from T1D. To this effect, it has previously been
demonstrated that treatment with glatiramer acetate prevents the
induction of experimental autoimmune encephalomyelitis (EAE)
in mice by inducing ‘‘semi-mature’’ type II monocytes (M2) that in
turn induce protective Tregs [16].
Susceptibility to T1D is dictated by a complex interplay
between genetic determinants and environmental influences
[17,18]. Among these environmental factors, viral infections have
long been associated with the development of T1D [19].
Particularly, coxsackieviral infections have been described as a
common precursor to T1D in patients [19] and the diabetogenic
properties of coxsackievirus B4 (CB4) infections have been well
documented in mouse models [20–22]. We have previously
demonstrated that CB4 infection of NOD mice increases
lymphocyte infiltration of the pancreas resulting in accelerated
disease onset [23]. Furthermore, the pancreatic islet pathology
observed following CB4 infection is characteristic of the pathology
associated with spontaneous disease progression in NOD mice. As
such, autoimmune diabetes acceleration following CB4 infection
represents an experimentally-controlled model that allows for
rapid modeling of therapies aimed at modulating diabetes onset.
Our prior work demonstrated that one consequence of CB4
infection was the infection of pancreatic b cells. Subsequently,
antigen presenting cells (APCs) engulfed the infected b cells for T
cell recognition and stimulation leading to an autoimmune attack
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infected NOD mice induced disease in non-diabetic recipient mice
[24,25]. Later, we observed that TGF-b through transgenic
expression or systemic administration established protection from
CB4-induced autoimmune diabetes [23]. This protection corre-
lated with the presence of ‘‘semi-mature’’ CD11b+CD11c2 APCs
expressing lower surface levels of costimulatory molecules as well
as an increase in pancreatic Tregs [23]. Interestingly, the capacity
of the host to clear viral infection remained unaffected. This
strongly suggested that APCs could be manipulated in order to
prevent autoimmunity without affecting the host’s response
to infection. Herein, we demonstrate that a reduction in the
inflammatory properties of CD11b+CD11c2 APCs is sufficient to
increase levels of pancreatic Tregs. Further, this increase in Tregs
which is observed following infection in the localized presence of
TGF-b is the result of an increase in the numbers of natural Tregs
rather than the phenotypic conversion of conventional T cells to
a Treg cells. Our results suggest that the development of
therapeutics aimed at modulating APC function and increasing
the levels of natural Tregs may represent a powerful tool for
reestablishing peripheral tolerance to beta cell antigen and
providing long-term protection from T1D.
Results
CD11b+CD11c2 APCs demonstrate reduced
inflammatory properties following CB4 infection in the
context of TGF-b
We previously demonstrated that CB4 infection in the context
of TGF-b protects from the induction of autoimmune diabetes
[23]. Protection was mediated by increased Treg cell numbers in
the pancreas and correlated with the reduced maturation of
CD11b+CD11c2 APCs as measured by costimulatory mole-
cule expression [23]. Here, we asked whether infection in the
presence of TGF-b affected other inflammatory properties of
these APCs. CD11b+CD11c2 (a population containing pre-
dominantly monocytes and macrophages) and CD11c+ (pre-
dominantly dendritic cells) cells from NOD and NODTGFb
mice were sorted by flow cytometry at day 7 following CB4
infection and cultured ex vivo for 24 hours. Cytokine secretion in
the culture supernatant was measured. Relative production of
the inflammatory cytokines TNF-a (Figure 1A,B) and IL-6
(Figure 1C,D) from CD11b+CD11c2 APCs purified from CB4
infected NODTGFb mice was significantly reduced compared to
the same population purified from CB4 infected NOD mice. No
significant production of IL-12p70, IFN-c or IL-2 was observed
(data not shown). Furthermore, while we observed no significant
production of the anti-inflammatory cytokine IL-10 (data not
shown), we observed a trend for increased TGF-b production
from CD11b+CD11c2 APCs purified from infected NODTGFb
mice although this difference did not reach statistical significance
(Figure S1). This suggests that the primary effect of TGF-b in
this model is to reduce the production of inflammatory cytokines
by APCs rather than to directly increase their production of anti-
inflammatory cytokines. Interestingly, infection in the context of
TGF-b did not affect the capacity of DCs to produce inflammatory
cytokines (Figure S2). This is supported by our previously published
data demonstrating that infection in the context of TGF-b did not
affect the maturation status of DCs [23]. Taken together, these data
demonstrate that CD11b+CD11c2 APCs with reduced inflamma-
tory properties are generated following CB4 infection in the context
of TGF-b.
Reduced production of inflammatory cytokines has been
previously associated with alternatively activated or type II
monocytes/macrophages (M2) [16]. As such, we asked whether
infection in the context of TGF-b resulted in the polarization of
monocytes/macrophages towards an M2 phenotype. To address
this question, we measured surface expression of the macrophage
scavenger receptor (MSR-A, CD204) and of the macrophage
mannose receptor (MMR, CD206), two markers associated with
M2 monocytes/macrophages [26], and of the negative costimu-
latory molecule programmed death ligand-1 (PD-L1, B7-H1), a
molecule associated with the maintenance of peripheral tolerance
[27]. No significant differences were observed in the percentage of
CD11b+CD11c2 APCs expressing CD204 or CD206 only or
both CD204 and CD206 between NOD and NODTGFb mice
prior to infection (Figure 2A) or at day 7 PI (Figure 2A, B).
Similarly, we observed no significant differences in PD-L1
expression between CD11b+CD11c2 APCs from NOD or
NODTGFb mice at day 7 following CB4 infection (Figure S3).
This suggests that following CB4 infection in the context of TGF-
b, monocytes/macrophages with a typical M2 phenotype are not
likely generated.
CD11b+CD11c2 APCs with reduced inflammatory
properties are sufficient to increase Treg levels in
uninfected NOD mice
Protection from autoimmune diabetes in mice expressing TGF-
b is mediated by an increased pancreatic Treg presence and
correlated with the induction of a ‘‘semi-mature’’ population of
CD11b+CD11c2 APCs [23]. As ‘‘semi-mature’’ APCs have been
previously associated with Treg induction [16], we asked whether
Figure 1. CD11b+CD11c2 APCs produce lower levels of
inflammatory cytokines following CB4 infection in the context
of TGF-b. Ex vivo production of A, B) TNF-a or C,D) IL-6 from
CD11b+CD11c2 APCs FACS sorted from CB4 infected NOD (black bar)
or NODTGFb (white bar) mice. Cytokine levels were measured from
culture supernatants following 24 hours of incubation. Panels A,C are
representative data from one experiment with pooled mice of each
genotype while panels B,D represent mean + s.e.m of cytokine levels
from 6 separate experiments normalized to the cytokine levels
produced by WT NOD mice infected with CB4 in each separate
experiments.
doi:10.1371/journal.pone.0031153.g001
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protective Tregs observed in NODTGFb mice following CB4
infection. CD11b+CD11c2 APCs were sorted by flow cytometry
from NOD or NODTGFb mice from mock-infected mice or at
day 7 PI with CB4 and adoptively transferred to uninfected 10–12
week old NOD mice. While transfer of CD11b+CD11c2 APCs
from uninfected NODTGFb mice was not sufficient to increase
Treg levels (Figure 3A), we observed a significant increase in Treg
levels in the PLNs (Figure 3B) and pancreas (Figure 3C) of NOD
mice that had been adoptively transferred with CD11b+CD11c2
APCs from NODTGFb mice compared to mock-transferred
NOD recipients. Conversely, adoptive transfer of the same
population purified from infected WT NOD mice was not
sufficient to significantly increase Treg levels in either the PLNs
(Figure 3B) or the pancreas (Figure 3C). This data builds on our
previous observations [23] and further strengthens the hypothesis
Figure 2. CB4 infection does not increase expression of type II
monocyte/macrophages markers on CD11b+CD11c-APCs. A)
Percentage of CD11b+CD11c2 APCs from mock-infected NOD (black
bars) or NODTGFb (white bars) mice positive for surface expression of
CD204, CD206 or CD204 and CD206. B) Percentage of CD11b+CD11c2
APCs from NOD (black bars) or NODTGFb (white bars) mice positive for
surface expression of CD204, CD206 or CD204 and CD206 7 days
following CB4 infection. Data represent mean + s.e.m from 3 separate
experiments, n=9 per group.
doi:10.1371/journal.pone.0031153.g002
Figure 3. Adoptive transfer of CD11b+CD11c2 APCs from CB4-
infected NODTGFb mice is sufficient to increase Treg levels in
uninfected NOD mice. Average percentage of CD4+ T cells
expressing Foxp3 in A, B) the PLNs or C) the pancreas of 10–12 week
uninfected NOD recipients mock-transferred with DMEM (grey bars) or
adoptively transferred with CD11b+CD11c2 APCs FACS sorted from A)
mock-infected NODTGFb mice (white bars) or B, C) CB4 infected
NODTGFb (white bars) or NOD mice (black bars). Data represent mean +
s.e.m. from at least 3 separate experiments (n=at least 6 mice per
group).
doi:10.1371/journal.pone.0031153.g003
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that functionally suppress the induction of autoimmune diabetes
following CB4 infection in the context of TGF-b. Importantly,
transfer of CD11b+CD11c2 APCs from uninfected NODTGFb
mice (Figure 3A) or NODTGFb mice infected with CB3, a closely
related virus strain that unlike CB4 does not infect pancreatic beta
cells, was not sufficient to increase Treg levels (Figure S4). This
suggests that infection of pancreatic beta cells and subsequent
presentation of self-antigen by ‘‘semi-mature’’ CD11b+CD11c2
APCs is an essential requirement for the induction of Tregs in vivo.
Reduced expression of CD40 on CD11b+CD11c2 APCs
favors Treg upregulation
CD11b+CD11c2 APCs from NODTGFb mice have previously
been demonstrated to express lower surface levels of costimulatory
molecules following CB4 infection [23]. As such, we asked whether
this ‘‘semi-mature’’ phenotypewas linkedto their capacity to induce
Tregs. To address the role of CD40, NOD mice deficient for CD40
(NODCD40KO) were infected with CB4. As these mice lack
transgene-driven pancreatic expression of TGF-b, this model allow
us to directly test the hypothesis that the reduction of CD40 on the
surface of CD11b+CD11c2 APCs following infection in the
context of TGF-b is part of the mechanism that favors Treg
increases. At day 7 PI, we observed a significant increase in Treg
levels in the PLNs (Figure 4A) and pancreas (Figure 4B) of infected
NODCD40KO mice compared to mock-infected mice suggesting
an important role for reduced surface expression of CD40 in
conferring CD11b+CD11c2 APCs with the capacity to induce
Tregs. In order to confirm the contribution of CD11b+CD11c2
APCs in increasing the Treg levels in NODCD40KO mice
following CB4 infection, CD11b+CD11c2 APCs were sorted by
flow cytometry from CB4 infected NODCD40KO mice and
adoptively transferred to uninfected 10–12 week old NOD mice. As
opposed to what we observed following CD11b+CD11c2 APC
transfer from CB4 infected CD40-competent NOD mice (Figure 3),
adoptive transfer of CD11b+CD11c2 APCs from CB4 infected
CD40-deficient NOD mice, but not mock-infected CD40-deficient
NOD mice, significantly increased levels of Tregs in the PLNs
compared to mock-transferred mice (Figure 4C). Taken together,
these data suggest that the protection from autoimmune diabetes
conferred by pancreatic expression of TGF-b is in part dictated by
the reduction of CD40 expression on CD11b+CD11c2 APCs that,
in turn, favors increases in Treg levels.
Treg upregulation results from an increase in natural
Tregs rather than conversion of conventional T cells to a
Treg phenotype
To better understand the mechanism of protection from T1D,
experiments were designed to determine how Tregs levels are
increased following CB4 infection in the local presence of TGF-b.
It has been well documented that T cell stimulation in the
presence of TGF-b can convert naı ¨ve T cells to a Treg phenotype
by inducing Foxp3 expression [28–31]. As such, we asked whether
Tregs increases observed in NODTGFb mice following CB4
infection resulted from phenotypic conversion of conventional
effector T cells to regulatory T cells or rather an increase in the
numbers of natural regulatory T cells. To differentiate increases in
natural Tregs from the induction of adaptive Tregs, we measured
Figure 4. Absence of CD40 on CD11b+CD11c2 APCs is
sufficient to increase Treg levels following CB4 infection.
Average percentage of CD4 T cells expressing Foxp3 in the A) PLNs
or B) pancreas of NODCD40KO mice mock-infected with DMEM (white
bars) or infected with CB4 (black bars) (n=at least 10 per group). C)
Average percentage of CD4+ T cells expressing Foxp3 in the PLNs of
uninfected 10–12 week old NOD mice mock-transferred with DMEM
(white bar) or adoptively transferred with CD11b+CD11c2 FACS sorted
from CB4 infected NODCD40KO (black bar) or mock-infected
NODCD40KO mice (grey bars). Data represent mean + s.e.m from at
least 3 separate experiments (n=at least 7 per group).
doi:10.1371/journal.pone.0031153.g004
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a recently described marker specifically expressed by thymically-
derived natural Tregs but not by Tregs induced by peripheral
conversion [32]. Following infection in the localized presence of
TGF-b, we observed a significant increase in the percentage of
Tregs that express Helios in the PLN of mice with increased Treg
levels (Figure 5 A,B). Conversely, the percentage of Tregs not
expressing Helios remained unchanged following infection. These
results strongly suggest that the increased Treg levels observed
following infection in the localized presence of TGF-b result from
an increase in natural Tregs rather than the conversion of
conventional T cells.
To confirm the observed lack of T cell conversion to Tregs,
experiments were designed to test whether CB4 in the context of
TGF-b was sufficient to induce conversion of conventional T cells
to a regulatory phenotype by inducing the expression of foxp3.
NODThy1.1 mice were crossed with previously described NOD
mice expressing a Foxp3
GFP reporter [33,34]. Conventional T
cells were sorted by flow cytometry as CD4+GFP2 cells and
adoptively transferred in 10–12 week old NOD or NODTGFb
recipients (expressing the Thy1.2 allele allowing for the differen-
tiation of donor cells). Mice were challenged with CB4 at 24 hours
post-transfer and analyzed by flow cytometry at day 7 PI. These
experiments were performed using viral infection rather than
adoptive transfer as viral infection yields a more robust increase in
Treg levels allowing for a better characterization of the induced
population. CD4 T cells of donor origin (Thy1.1+) were readily
identifiable in the spleen, PLNs and pancreas of both NOD and
NODTGFb mice (Figure 5 and data not shown). However, none
of the recovered donor CD4 T cells were positive for GFP in either
NOD or NODTGFb recipients indicating that infection in the
local presence of TGF-b does not induce Foxp3 expression in CD4
T cells (Figure 5C). These results confirm the data obtained by
helios staining and demonstrate that increases in Tregs observed in
this model result from an increase in natural regulatory T cells.
Discussion
It is becoming increasingly clear that defects in peripheral
tolerance are linked to the development of T1D. Specifically, a
decline in the capacity of Tregs to suppress autoreactive T cells has
been associated with disease progression in both humans and mice
[35]. Recent evidence has demonstrated that this decline in
suppressive capacity is not due to Treg intrinsic defects but rather
to changes at the level of APCs [12–14]. Here, we demonstrate
that CD11b+CD11c2 APCs with reduced inflammatory proper-
ties are accountable for an increase in pancreatic Treg levels.
A link between the CD11b+CD11c2 subset of APCs and the
declining function of Tregs in NOD mice has been recently
established [12]. As such, our findings suggest that therapies aimed
at targeting the inflammatory properties of CD11b+CD11c2
APCs may represent a long-term solution to reestablishing
peripheral tolerance to pancreatic antigens. In this regard, it has
been demonstrated that glatiramer acetate treatment protects from
autoimmunity in a mouse model of multiple sclerosis (MS) by
acting at the levels of APCs. Specifically, drug treatment reduced
the maturation status and inflammatory properties of CD11b+
monocytes and increased their capacity to induce Tregs [16]. The
similarities in phenotypes observed in the MS model and in NOD
mice infected with CB4 in the context of TGF-b suggest that
glatiramer acetate treatment may represent a potential therapeutic
avenue for the treatment of T1D. Interestingly, glatiramer acetate
treatment of NOD mice increased Treg levels and partially
protected from cyclophosphamide-induced T1D acceleration [36].
Similarly, treatment with complete Freund’s adjuvant has also
been demonstrated to modulate the capacity of APCs from the
NOD mice to maintain regulatory T cell function and protect
Figure 5. CB4 infection in the context of TGF-b does not induce
conversion of naı ¨ve T cells to adaptive Tregs but rather
increases the levels of natural Tregs. A) Representative flow
cytometry plots of Foxp3 and Helios expression by CD4+ T cells from
the PLNs of mock-infected (left panel) or CB4-infected NODTGFb mice
at day 7PI. B) Average percentage of Helios+ cells among CD4+Foxp3+
Tregs from the PLNs of NODTGFb mice with increased Treg levels at day
7 PI with CB4 (black bars) or mock-infection with DMEM (white bars). C)
Average percentage of Helios- cells among CD4+Foxp3+ Tregs from the
PLNs of NODTGFb mice with increased Treg levels at day 7 PI with CB4
(black bars) or mock-infection with DMEM (white bars). Data represent
mean + s.e.m from at least 2 separate experiments (n=at least 4 per
group). D) Representative flow cytometry plots of CD4 and GFP (Foxp3)
expression of donor (Thy1.1+) cells recovered from the spleen (left
panels) or PLNs (right panels) of NOD (top panels) or NODTGF-b
(bottom panels) recipient mice at day 7 following infection with CB4.
Data is representative of 2 separate experiments, n=3 for NOD
recipients and n=6 for NODTGFb recipients.
doi:10.1371/journal.pone.0031153.g005
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demonstrated that recombinant adeno-associated virus can be
used to express constructs under the control of an insulin promoter
specifically within the islets [38,39]. This suggests that this
approach could be adopted to modulate the inflammatory
properties of APCs directly within the pancreas and these studies
are currently ongoing with Kieffer and colleagues. Taken together,
these data strongly suggest that CD11b+CD11c2APCs represent
a key target for therapies aiming to reestablish tolerance and
protect from T1D. Importantly, our prior work clearly established
that manipulating the inflammatory status of these APCs does not
affect the capacity of the host to respond to viral infection strongly
suggesting that targeting this subset of APCs would not result in
generalized immunosuppression [23].
The capacity of CD11b+CD11c2 APCs to increase Tregs
following infection in the localized presence of TGF-b is correlated
with three important features. First, we previously demonstrated
that CD11b+CD11c2 APCs present with a ‘‘semi-mature’’
phenotype characterized by reduced surface expression of
costimulatory molecules [23]. Here, we further demonstrate that
reduced expression of CD40 plays a role in the heightened
capacity of CD11b+CD11c2 APCs from NOD mice to increase
Treg levels. This strongly suggests that while CD40 signals are
likely involved in the acceleration of T1D by CD11b+CD11c2
APCs following CB4 infection, reduction or absence of these
signals tips the balance towards Treg induction. This is supported
by data demonstrating that blockade of CD40/CD154 interac-
tions through genetic ablation of either molecule or blocking
antibody treatment is associated with decreased alloimmune
responses and increased transplant tolerance [40]. Interestingly,
CD40 deficiency has previously been demonstrated to result in
reduced Treg frequency in the periphery suggesting a role for
CD40 in Treg homeostasis. While we observed that, similar to
other mouse models [41,42], baseline Treg levels were lower in
NOD mice lacking CD40 compared to WT NOD, our results
clearly demonstrate that under inflammatory conditions reduced
CD40 expression favors Treg increases. This suggests that under
inflammatory conditions, CD40 expression may act to control the
balance between activation of effectors and immunoregulation by
Tregs [7,43]. As such, therapies aimed at reducing CD40
expression on CD11b+CD11c2 may prove particularly effective
at reestablishing Treg function and peripheral tolerance. Second,
CD11b+CD11c2 APCs generated following CB4 infection
produce lower levels of the inflammatory cytokines TNF-a and
IL-6. This may have several effects on disease progression. In
particular, autoimmune diabetes acceleration following CB4
infection has been hypothesized to progress through a bystander
activation mechanism that relies upon presentation of previously
sequestered antigens in an inflammatory milieu [20]. As such,
reduced inflammation likely curtails the activation and/or
expansion of autoreactive T cells and this will be the subject of
future investigation. IL-6 has previously been associated with
blocking Treg suppressive capacities [44] and preventing the
expression of the Treg specific transcription factor Foxp3 in order
to favor the generation of Th17 clones [45]. As such, decreased IL-
6 production may be linked to the capacity of CD11b+CD11c2
APCs from NODTGFb mice to increase Treg levels. Third,
infection of pancreatic beta cells appears to be a critical
requirement for the induction of Tregs by CD11b+CD11c2
APCs. This strongly suggests that the presentation of pancreatic
self-antigens by semi-mature APCs favors the generation of
protective Tregs in this model. This likely occurs directly within
the pancreas, however, attempts to determine this histologically
have been hampered by the destruction of exocrine tissue induced
by coxsackieviral infection. Furthermore, depletion experiments
aiming to confirm the data from the adoptive transfer experiments
presented in this manuscript are hampered by the critical role of
macrophages in the response to viral infection [46]. As such, any
attempt to deplete macrophages in this system would result in
virus-induced mortality.
Taken together, our data demonstrate that protection from
T1D is linked to a decrease in the capacity of CD11b+CD11c2
APCs to activate autoreactive responses and an increase in their
immunoregulatory properties. As such, therapies aimed at this
particular APC subset may have a two-fold protective effect by
reducing the capacity of these cells to drive autoimmune pathology
and favoring their capacity to induce protective mechanisms.
Interestingly, despite the localized expression of TGF-b directly
within the pancreatic islets, we observed that APCs isolated from
the spleen of CB4-infected NODTGFb mice present with
immunoregulatory properties. This suggests that while APCs
appear to acquire antigen and become tolerogenic directly within
the pancreas they retain the ability to recirculate to mediate their
immunomodulatory functions. This is supported by data demon-
strating that NODTGFb mice are protected for coxsackievirus-
induced autoimmune myocarditis and that this protection is
dependent upon infection of the pancreas and correlates with
modulation of APCs [47,48]. This strongly suggests that locally
modulated APC population can induce protection from autoim-
munity at distal sites.
The generation of protective Tregs following infection in the
context of TGF-b may represent an extension of a natural process
that allows maintenance of tolerance to self-antigens, following
viral infections. Infections with LCMV have long been described
to protect NOD mice from the development of T1D [49]. This
protection is associated with increases in several immunoregula-
tory mechanisms that are likely activated to prevent immunopa-
thology following the resolution of an antiviral response. In
particular, this was associated with increased TGF-b production
and increased levels of Tregs that protect from the induction of
autoimmune diabetes [50]. This suggests that any mechanism that
serves to increase the production of TGF-b may be sufficient to
reestablish long-term tolerance and protect from T1D.
Finally our data demonstrate that the heightened Treg levels
observed following infection in the context of TGF-b are not due
to conversion of naı ¨ve T cells to a regulatory phenotype. Rather,
our data demonstrate that the increase in Tregs results from an
increase in Helios expressing natural Tregs [32]. This suggests
than in addition to its well-described capacity to contribute to the
conversion of conventional T cells to a Treg phenotype,
stimulation of T cells in the presence of TGF-b can also result
in an overall increase in the presence of natural Tregs. Although
the mechanism responsible for this increase in natural Tregs
remains undefined, our preliminary data suggest that this does not
result from an increase in Treg survival or an increase in the
proliferative capacity of Tregs (Richer and Horwitz, unpublished
observations). Of particular interest, Foxp3 expression was
recently described to be unstable in NOD mice and loss of Foxp3
expression yields inflammatory cells that can contribute to T1D
pathogenesis [51]. It is possible that CB4 infection in the context of
TGF-b may function to stabilize Foxp3 expression and this
warrants further investigation. Interestingly, Thornton and
colleagues have recently demonstrated that natural Tregs
expressing Helios appear less likely to gain an inflammatory
phenotype than peripherally converted Tregs lacking Helios [32].
As such, therapies aimed at increasing the levels of Helios
expressing natural Tregs may prove particularly effective at
preventing autoimmune diseases such as T1D. Furthermore, the
Modulation of APCs Increases Protective nTregs
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progression of autoimmune diabetes in NOD mice remains to
be addressed and should be the subject of further investigation.
In conclusion, our results demonstrate that the inflammatory
properties of CD11b+CD11c2APCs can be modulated to yield a
subset of APCs with immunoregulatory properties. We provide
evidence that reducing the inflammatory properties of this APC
subset is sufficient to switch the effects of CB4 infection from a
diabetogenic [24] to a protective role. Taken together with
evidence that the decline in Treg function associated with disease
progression is not due to Treg intrinsic defects but rather to a
reduction in the capacity of this APC subset to maintain Treg
function [12], this argues for the targeting of this APC subset as a
powerful therapeutic tool for the long-term reestablishment of
peripheral tolerance to beta cell antigens.
Materials and Methods
Mice
NOD/ShiLtJ mice were obtained from The Jackson Laboratory
(Bar Harbor, USA). NODTGFb transgenic mice expressing TGF-b
under the control of the human insulin promoter were generated in
the laboratory of Dr. N. Sarvetnick (University of NebraskaMedical
Center, Omaha, NE, USA) and have been previously characterized
[23,52]. NODCD40KO and NODThy1.1 and NODFoxp3
GFP
mice were obtained from the JDRF Center on Immunological
Tolerance at Harvard Medical School. All mice were bred and
maintained in our rodent facility and tested for diabetes prior
to infection. Mice with two consecutive non-fasting blood glucose
readings of .300mg/dl were considered diabetic. Animals
experiments were approved, conform and were performed to the
guidelines of the Animal Care Committee at the University of
British Columbia which ensures that appropriate care, including
adequate veterinary care, is given to animals in all stages of life and
in all experimental situations in compliance with Canadian Council
on Animal Care (‘‘CCAC’’) guidelines and CALAM Standards of
Veterinary Care. This work was approved by the UBC ACC and
the approved animal protocol number is AO8-0622.
Virus
Stocks of CB4 Edwards strain 2 and CB3 Nancy strain were
obtained and prepared as described previously [47,53]. 10–12
week old mice were infected intraperitoneally with sublethal doses
of 400 plaque forming units (PFU) of virus diluted in DMEM,
mock-infected mice received an equivalent volume of DMEM.
Flow cytometry
Single cell suspensions were stained for the appropriate markers
and analyzed by flow cytometry on an LSRII cell analyzer (BD
Biosciences, Missisauga, Canada). Fluorescently conjugated anti-
bodies directed against CD11b (clone M1/70), CD11c (clone
N418), PD-L1 (clone M1H5), CD4 (clone L3T4), CD25 (clone
PC61), BCL2 (clone 10C4) and Foxp3 (clone FJK-16s) were
purchased from eBiosciences (San Diego, USA). Fluorescently
conjugated antibodies directed against CD204 (clone 2F8) and
biotin-conjugated antibodies directed against CD206 (clone
MR5D3) were purchased from AbD Serotec (NC, USA).
Fluorescently conjugated antibodies directed against Helios were
purchased from BioLegend (San Diego, USA). Data were
analyzed with FlowJo software (Tree Star).
APC adoptive transfer
Single cell suspensions were generated from spleens of CB4
infected mice at day 7 post-infection (PI). Cells were stained with
fluorescently conjugated antibodies directed against CD11b and
CD11c and sorted on a FACSAria flow cytometer (BD Bioscience,
Missisauga, Canada). 2610
5 purified CD11b+CD11c2 diluted in
DMEM were adoptively transferred intraperitoneally into unin-
fected NOD mice. Spleens, pancreata and pancreatic lymph nodes
(PLNs) were harvested at day 7 post-transfer for Treg analysis.
Mock-transferred mice received an equivalent volume of DMEM.
Ex vivo cytokine analysis
CD11b+ CD11c2 cells and CD11c+ cells were sorted by flow
cytometry as described above and 1610
5 cells were cultured for
24 hours at 37uC in IMDM containing 10% fetal bovine serum.
Supernatants were harvested and cytokine levels were measured
using a BD CBA inflammation kit (BD Bioscience, Missisauga,
Canada) or a Mouse TGF-b1 ELISA Ready-SET-Go! kit from
eBioscience (San Diego, USA) Samples were prepared according
to manufacturer’s instructions and bead array samples were
analyzed on a BDFacsArray equipped with FCAP software
(BDBiosciences). Cytokine levels were normalized and are
presented as a percentage of cytokine production compared to
similarly infected WT NOD mice.
Isolation of pancreatic infiltrating cells
Pancreata were isolated from infected NOD and NODTGFb
mice and mechanically disrupted. Single cell suspensions were
treated for 10 minutes at 37uC in a PBS solution containing 1 mg/
ml of collagenase. Recovered cells were stained for flow cytometry.
Treg conversion assay
Single cell suspension from NODFoxp3GFPThy1.1 mice were
stained with fluorescently conjugated antibodies directed against
CD4 and sorted by flow cytometry. 2610
6 CD4+GFP2 (non-
Tregs) cells were adoptively transferred intraperitoneally into
NOD mice or NODTGFb mice 24 hours prior to infection with
400 pfu of CB4. At day 7 post-infection, conversion to a Treg
phenotype was analyzed by measuring GFP (Foxp3) expression in
CD4+Thy1.1+ cells from the spleen, pancreas and PLNs.
Statistical analysis
Statistical analysis was performed with Prism GraphPad
software. The unpaired Student’s t-test was used for statistical
analysis. A P value of less than 0.05 was considered significant.
Supporting Information
Figure S1 CD11b+CD11c2 APCs do not produce signif-
icantly higher levels of TGF-b following CB4 infection in
the context of TGF-b. Ex vivo production TGF-b from
CD11b+CD11c2 APCs FACS sorted from CB4 infected NOD
(black bar) or NODTGFb (white bar) mice. Cytokine levels were
measured from culture supernatants following 24 hours of
incubation. Data represent mean + s.e.m of normalized cytokine
levels from pooled mice in 3 separate experiments.
(EPS)
Figure S2 CB4 infection in the context of TGF-b does not
affect the capacity of DCs to produce cytokines. Ex vivo
production of A) TNF-a or B) IL-6 from CD11c+ DCs FACS
sorted from CB4 infected NOD (black bar) or NODTGFb (white
bar) mice. Data represent mean + s.e.m of normalized cytokine
levels from pooled mice in 3 separate experiments.
(EPS)
Figure S3 CD11b+CD11c2 APCs from NODTGFb mice
do not express increased levels of PD-L1 compared NOD
Modulation of APCs Increases Protective nTregs
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31153mice following CB4 infection. A) Representative histogram of
surface PD-L1 expression on CD11b+CD11c2 APCs from NOD
(black line) or NODTGFb (grey line) mice at day 7 following CB4
infection. B) Average mean fluorescence intensity of PD-L1
expression on the surface of CD11b+CD11c2 APCs from NOD
(black bar) or NODTGFb (white bars) mice at day 7 following
CB4 infection. Data represent mean + s.e.m. from 2 separate
experiments (n=at least 5 per group.).
(EPS)
Figure S4 Adoptive transfer of CD11b+CD11c2 APCs
from CB3-infected NODTGFb mice is not sufficient to
increase Treg levels in uninfected NOD mice. Average
percentage of CD4+ T cells expressing Foxp3 in the PLNs of 10–
12 week uninfected NOD recipients mock transferred with
DMEM (grey bars) or adoptively transferred with
CD11b+CD11c2 APCs FACS sorted from CB3 infected
NODTGFb (white bars) mice. Data represent mean + s.e.m.
from 3 separate experiments (n=at least 6 per group).
(EPS)
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